UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 15, 2015

 


 

Onconova Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)

 


 

Delaware

 

001-36020

 

22-3627252

(State or Other Jurisdiction
of Incorporation or Organization)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

 

375 Pheasant Run
Newtown, PA 18940
(267) 759-3680

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

 

Not Applicable

(Former name or former address, if changed since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

 

o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On June 15, 2015, Onconova Therapeutics, Inc. (the “Company”) held its 2015 Annual Meeting of Stockholders. At the Annual Meeting, the Company’s stockholders voted on the following proposals:

 

1. To elect the seven nominees named in the Company’s proxy statement to serve for a one-year term as a director of the Company expiring at the Company’s 2016 Annual Meeting of Stockholders and, in each case, until a successor is elected and qualified. Each nominee for director was elected by a vote of the stockholders as follows:

 

Name

 

For

 

Withheld

 

Broker Non-Votes

 

 

 

 

 

 

 

 

 

Henry S. Bienen

 

10,630,183

 

116,416

 

4,770,055

 

 

 

 

 

 

 

 

 

Jerome E. Groopman

 

10,630,026

 

116,573

 

4,770,055

 

 

 

 

 

 

 

 

 

Michael B. Hoffman

 

10,625,370

 

121,229

 

4,770,055

 

 

 

 

 

 

 

 

 

Ramesh Kumar

 

10,611,270

 

135,329

 

4,770,055

 

 

 

 

 

 

 

 

 

Viren Mehta

 

10,599,667

 

146,932

 

4,770,055

 

 

 

 

 

 

 

 

 

E. Premkumar Reddy

 

10,613,851

 

132,748

 

4,770,055

 

 

 

 

 

 

 

 

 

Anne M. VanLent

 

10,628,326

 

118,273

 

4,770,055

 

 

2. To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2015. The proposal was approved by a vote of the stockholders as follows:

 

For

 

Against

 

Abstain

 

 

 

 

 

 

 

15,346,023

 

106,693

 

63,938

 

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 16, 2015

Onconova Therapeutics, Inc.

 

 

 

By:

/s/ Ajay Bansal

 

 

Name: Ajay Bansal

 

 

Title: Chief Financial Officer

 

3